{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:01:14Z","timestamp":1769882474014,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Intravenous immunoglobulins (IVIg) are the first-choice drugs for the treatment of certain neuroimmune diseases. The aim of this study was to evaluate the efficacy and safety of IVIg in patients with selected nervous system diseases. Methods: The study enrolled patients who received IVIg in programmes financed by the National Health Fund in Poland. The status of patients upon inclusion and during treatment was assessed using scales dedicated to specific neurological diseases. Results: The study enrolled 141 patients aged 56.28 \u00b1 14.72 (51.77% female): 21 patients with myasthenia gravis (MG), 65 with chronic inflammatory demyelinating polyneuropathy (CIDP), 30 with Guillain\u2013Barr\u00e9 syndrome (GBS), 12 with neuromyelitis optica spectrum disorder (NMOSD) and 13 patients with autoimmune encephalitis (AE). Neurological improvement was found in 14 (66.66%) MG patients (with a reduction of at least three points on the Quantitative Myasthenia Gravis Score (QMGS) within 14 days from the completion of the cycle), and in 34 (52.3%) GBS patients (with a reduction of at least one point on the Medical Research Council Scale within 14 days from the completion of the cycle). The parameters with the strongest effect on clinical improvement in MG patients were age [OR 1.033, CI 95% [0.09\u20131.09], p = 0.049] and baseline QMGS [OR 0.505; CI 95% [0.24\u20130.87], p = 0.038]. In the majority of CIDP patients (27, 97%) and NMOSD patients (6, 50%), neurological stabilisation was observed (without clinical improvement, defined for CIDP patients as an increase of at least two points on the Lovett Scale after three courses of IVIg were administered, and for NMOSD patients as an increase of at least one point on the Medical Research Council Scale and\/or a shift of at least 0.3 logMAR after three courses of treatment). Deep-vein thrombosis was only one serious adverse event in the total group of patients treated with IVIg. Conclusions: The use of IVIg in patients with MG and GBS mostly results in neurological improvement, while in patients with NMOSD and CIDP, it mostly results in disease stabilisation. This could indicate the predominant anti-idiotypic antibody activity of IVIg in acute neuroimmune diseases or during exacerbations in chronic autoimmune diseases. The therapy of AE in comorbid neoplastic disease is burdened with an elevated risk of failure for IVIg. The results of our study confirm the improved safety of IVIg for selected neurological diseases.<\/jats:p>","DOI":"10.3390\/jcm12185983","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:06:13Z","timestamp":1694750773000},"page":"5983","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Intravenous Immunoglobulin Treatment in Selected Neurological Diseases\u2014One Centre\u2019s Experience Based on the Therapy of 141 Patients"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-7528","authenticated-orcid":false,"given":"Anetta","family":"Lasek-Bal","sequence":"first","affiliation":[{"name":"Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Zio\u0142owa Str. 45\/47, 40-735 Katowice, Poland"},{"name":"Department of Neurology, Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, 40-735 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-7018","authenticated-orcid":false,"given":"Anna","family":"Wagner-Kusz","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Zio\u0142owa Str. 45\/47, 40-735 Katowice, Poland"},{"name":"Department of Neurology, Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, 40-735 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rogo\u017c","sequence":"additional","affiliation":[{"name":"Department of Neurology, Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, 40-735 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Cisowska-Babraj","sequence":"additional","affiliation":[{"name":"Department of Neurology, Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, 40-735 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Gajewska","sequence":"additional","affiliation":[{"name":"Department of Neurology, Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, 40-735 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737175.2022.2169134","article-title":"Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Mechanisms of action and clinical and genetic considerations","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev. Neurother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-onset Myasthenia Gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther. Apher. Dial."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability Testing of the Quantitative Myasthenia Gravis Scorea","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: Chronological surveys over 10 years","volume":"14","author":"Suzuki","year":"2022","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"ref_7","first-page":"103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/mus.23236","article-title":"Predictors of response to immunomodulation in patients with myasthenia gravis","volume":"45","author":"Katzberg","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17562864231154306","DOI":"10.1177\/17562864231154306","article-title":"Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: A systematic literature review","volume":"16","author":"Pinto","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00415-021-10908-9","article-title":"Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy","volume":"269","author":"Talaei","year":"2021","journal-title":"J. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies","volume":"18","author":"Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chan, K.-H., and Lee, C.-Y. (2021). Treatment of Neuromyelitis Optica Spectrum Disorders. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168638"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5603\/PJNNS.a2022.0044","article-title":"Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder","volume":"56","author":"Topkan","year":"2022","journal-title":"Neurol. I Neurochir. Pol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Saitakis, G., and Chwalisz, B.K. (2022). Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179769"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10384-020-00790-9","article-title":"Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: A multicenter, double-blind, randomized, controlled phase III study","volume":"65","author":"Mimura","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014First revision","volume":"17","author":"Hadden","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/jnnp-2014-309042","article-title":"Intravenous immunoglobulin response in treatment-nai ve chronic inflammatory demyelinating polyradiculoneuropathy","volume":"86","author":"Kuitwaard","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/ene.14742","article-title":"Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_20","first-page":"S1","article-title":"Encefalitis autoinmunes","volume":"66","author":"Verdaguer","year":"2018","journal-title":"Rev. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-Mediated Encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7861\/clinmed.2020-0241","article-title":"Update on the diagnosis and management of autoimmune encephalitis","volume":"20","author":"Ellul","year":"2020","journal-title":"Clin. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10072-019-03930-3","article-title":"Management of antibody-mediated autoimmune encephalitis in adults and children: Literature review and consensus-based practical recommendations","volume":"40","author":"Zuliani","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5603\/PJNNS.a2020.0045","article-title":"Safety and tolerability of therapeutic plasma exchange in autoimmune neurological diseases\u2014A retrospective single-centre analysis","volume":"54","author":"Mazur","year":"2020","journal-title":"Neurol. Neurochir. Polska"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5983\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:51:33Z","timestamp":1760129493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":25,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12185983"],"URL":"https:\/\/doi.org\/10.3390\/jcm12185983","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]}}}